As they described in Radiology Case Reports, the patient noted that she had been having increasing weakness in her left arm ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Skyclarys (omaveloxolone) to treat Friedreich's ataxia in ...

FRIENDSWOOD, Texas — A new master-planned community with around 2,800 single-family homes is coming to the Baybrook Mall area off Interstate 45 southeast of Houston, with first homes expected ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved omaveloxolone (Skyclarys), the first treatment for patients aged 16 and over, in the UK for a rare neurodegenerative ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood —and for the hundreds of Canadians who live with it, the lack of ...

Stemchymal® is an allogeneic adipose-derived mesenchymal stem cell (MSC) therapy developed for spinocerebellar ataxia (SCA), a rare neurodegenerative disease that is currently incurable.

Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first treatment for patients aged 16 years and older with the rare ...

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on outcomes the biotech plans to use as co-primary endpoints in a ...

A cohort was assessed of 204 adult participants, 102 with an existing large joint implant (median age 71.7) and 102 in a control group that had never received joint replacement surgery (median age ...